# Study to Evaluate the Safety and Efficacy of CAT-354

> **NCT00873860** · PHASE2 · COMPLETED · sponsor: **MedImmune LLC** · enrollment: 357 (actual)

## Conditions studied

- Asthma

## Interventions

- **OTHER:** Placebo
- **BIOLOGICAL:** CAT-354 150 mg
- **BIOLOGICAL:** CAT-354 300 mg
- **BIOLOGICAL:** CAT-354 600 mg

## Key facts

- **NCT ID:** NCT00873860
- **Lead sponsor:** MedImmune LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-06
- **Primary completion:** 2010-08
- **Final completion:** 2010-08
- **Target enrollment:** 357 (ACTUAL)
- **Last updated:** 2017-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00873860

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00873860, "Study to Evaluate the Safety and Efficacy of CAT-354". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00873860. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*